AZISIGN 250 Tablet is a high-quality macrolide antibiotic manufactured to address a broad spectrum of bacterial infections effectively. Each tablet contains 250 mg of Azithromycin, an active pharmaceutical ingredient well-regarded for its powerful antibacterial properties. Azithromycin is a semisynthetic derivative of erythromycin and has a broader antimicrobial spectrum along with better tissue penetration and improved pharmacokinetic properties. It works by binding to the 50S ribosomal subunit of susceptible bacteria, thereby inhibiting bacterial protein synthesis. This process prevents the bacteria from growing and replicating, allowing the immune system to clear the infection more efficiently.

AZISIGN 250 is prescribed for the treatment of numerous bacterial infections, particularly those affecting the respiratory system, including pharyngitis, tonsillitis, bronchitis, and community-acquired pneumonia. It is also widely used for skin and soft tissue infections such as cellulitis, impetigo, and infected wounds. In ENT infections, including sinusitis and otitis media, Azithromycin proves to be a dependable choice due to its ability to reach effective concentrations in inflamed tissues. Moreover, it is indicated for certain urogenital infections, including uncomplicated urethritis and cervicitis caused by Chlamydia trachomatis.

One of the key advantages of AZISIGN 250 is its extended half-life, which allows for once-daily dosing and shorter treatment durations, typically ranging from three to five days. This unique feature enhances patient compliance and therapeutic outcomes, particularly when compared to antibiotics that require multiple daily doses over longer periods. The drug is absorbed quickly when taken orally and reaches peak plasma levels within two to three hours. It accumulates effectively in tissues such as the lungs, tonsils, and skin, maintaining bactericidal concentrations for several days even after the final dose.